Isonics Corporation To Present at Rodman & Renshaw's 3rd Annual Security, Biodefense & Connectivity Investor Conference on Monday, June 19th.

GOLDEN, Colo. -- Isonics Corporation (Nasdaq:ISON), a provider of innovative solutions for the homeland security and semiconductor markets, announced today that James Alexander, Isonics' Chairman & CEO, will present at 2:50 p.m. eastern time on Monday, June 19, 2006 at the Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference taking place at the St. Regis Hotel in New York City.

Mr. Alexander will present the company strategy, product portfolio and business outlook. The format of the Conference will include the company presentation, a breakout session, and one-on-one meetings, as well as a featured guest speaker, General Wesley Clark. More than 600 delegates, including institutional investors, venture capitalists, and senior corporate executives as well as experts from the scientific and government communities, are registered to attend the event.

Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. During the last two years, Rodman & Renshaw completed over 60 financing transactions, totaling over $1 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors.

About Isonics Corporation

Isonics Corporation has three business divisions: (1) Homeland Security and Defense (2) Semiconductor, and (3) Life Sciences. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals, silicon-on-insulator wafers, wafer reclaim services and test wafers, including 300mm, for the semiconductor industry. Isonics' Life Sciences division markets and sells isotopes to the health care industry for the imaging and treatment of cancer. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Additional information may be obtained at the Company's Web site at www.isonics.com.

Cautionary Statement

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve estimates, assumptions, known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB for the year ended April 30, 2005 and reports subsequently filed with the Securities and Exchange Commission, which include the Company's historical cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in these filings with the Securities and Exchange Commission.